scholarly journals Structural basis for Ca2+ activation of the heteromeric PKD1L3/PKD2L1 channel

2021 ◽  
Vol 12 (1) ◽  
Author(s):  
Qiang Su ◽  
Mengying Chen ◽  
Yan Wang ◽  
Bin Li ◽  
Dan Jing ◽  
...  

AbstractThe heteromeric complex between PKD1L3, a member of the polycystic kidney disease (PKD) protein family, and PKD2L1, also known as TRPP2 or TRPP3, has been a prototype for mechanistic characterization of heterotetrametric TRP-like channels. Here we show that a truncated PKD1L3/PKD2L1 complex with the C-terminal TRP-fold fragment of PKD1L3 retains both Ca2+ and acid-induced channel activities. Cryo-EM structures of this core heterocomplex with or without supplemented Ca2+ were determined at resolutions of 3.1 Å and 3.4 Å, respectively. The heterotetramer, with a pseudo-symmetric TRP architecture of 1:3 stoichiometry, has an asymmetric selectivity filter (SF) guarded by Lys2069 from PKD1L3 and Asp523 from the three PKD2L1 subunits. Ca2+-entrance to the SF vestibule is accompanied by a swing motion of Lys2069 on PKD1L3. The S6 of PKD1L3 is pushed inward by the S4-S5 linker of the nearby PKD2L1 (PKD2L1-III), resulting in an elongated intracellular gate which seals the pore domain. Comparison of the apo and Ca2+-loaded complexes unveils an unprecedented Ca2+ binding site in the extracellular cleft of the voltage-sensing domain (VSD) of PKD2L1-III, but not the other three VSDs. Structure-guided mutagenic studies support this unconventional site to be responsible for Ca2+-induced channel activation through an allosteric mechanism.

2019 ◽  
Vol 49 (3) ◽  
pp. 233-240
Author(s):  
Akinari Sekine ◽  
Takuya Fujimaru ◽  
Junichi Hoshino ◽  
Tatsuya Suwabe ◽  
Masahiko Oguro ◽  
...  

Background: Genetic characteristics of polycystic kidney disease (PKD) patients without apparent family history were reported to be different from those with a positive family history. However, the clinical course of PKD patients with no apparent family history is not well documented in the literature. Methods: We evaluated the relationship between genotype and the clinical course of 62 PKD patients with no apparent family history. Results: The annual decline of renal function was faster in the patients with PKD1/PKD2 mutation (PKD1 truncating [–3.08; 95% CI –5.30 to –0.87, p = 0.007], PKD1 nontruncating [–2.10; –3.82 to –0.38, p = 0.02], and PKD2 [–2.31; –4.40 to –0.23, p = 0.03]) than in the other patients without PKD1/PKD2 mutation. Similar results were obtained after adjustment for gender, age, estimated glomerular filtration rate (eGFR), height-adjusted total kidney volume (TKV), and mean arterial pressure (MAP). There was no significant difference in the annual decline of renal function among the different PKD1/PKD2 groups, but Kaplan-Meier analysis showed that progression to eGFR < 15 mL/min/1.73 m2 was significantly faster in PKD1 truncating group (p = 0.05). The annual rate of TKV increase was larger in the patients with PKD1/PKD2 mutation (PKD1 truncating [4.63; 95% CI 0.62–8.64, p = 0.03], PKD1 nontruncating [3.79; 0.55–7.03, p = 0.02], and PKD2 [2.11; –1.90 to 6.12, p = 0.29]) than in the other patients without PKD1/PKD2 mutation. Similar results were obtained after adjustment for gender, age, eGFR, and MAP. Conclusion: Detection of PKD1/PKD2 mutation, especially PKD1 truncating, is useful for predicting the renal outcome and rate of TKV increase in PKD patients with no apparent family history.


1994 ◽  
Vol 46 (1) ◽  
pp. 134-152 ◽  
Author(s):  
Katrin Schäfer ◽  
Norbert Gretz ◽  
Michael Bader ◽  
Ilse Oberbäumer ◽  
Kai-Uwe Eckardt ◽  
...  

1995 ◽  
Vol 4 (4) ◽  
pp. 559-567 ◽  
Author(s):  
Jeffrey J. Schrick ◽  
L.F. Onuchic ◽  
S.T. Reeders ◽  
J. Korenberg ◽  
X-N. Chen ◽  
...  

1998 ◽  
Vol 9 (9) ◽  
pp. 749-752 ◽  
Author(s):  
P. Pennekamp ◽  
N. Bogdanova ◽  
M. Wilda ◽  
A. Markoff ◽  
H. Hameister ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document